Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is Paradigm Biocapital Advisors LP's 6th Largest Position

Paradigm Biocapital Advisors LP increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 3.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,531,896 shares of the company's stock after buying an additional 91,451 shares during the period. Tarsus Pharmaceuticals comprises about 4.9% of Paradigm Biocapital Advisors LP's portfolio, making the stock its 6th biggest position. Paradigm Biocapital Advisors LP owned 6.62% of Tarsus Pharmaceuticals worth $140,191,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in TARS. Barclays PLC increased its stake in Tarsus Pharmaceuticals by 345.9% in the third quarter. Barclays PLC now owns 98,663 shares of the company's stock valued at $3,246,000 after purchasing an additional 76,538 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Tarsus Pharmaceuticals by 0.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company's stock valued at $63,499,000 after purchasing an additional 5,565 shares during the last quarter. R Squared Ltd purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $53,000. Baader Bank Aktiengesellschaft purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $249,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Tarsus Pharmaceuticals by 10.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company's stock valued at $449,000 after purchasing an additional 789 shares during the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock traded up $0.20 during midday trading on Friday, reaching $43.70. The company's stock had a trading volume of 485,472 shares, compared to its average volume of 699,829. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock's 50 day simple moving average is $48.05 and its 200 day simple moving average is $49.17. The firm has a market capitalization of $1.84 billion, a PE ratio of -11.47 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. On average, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insider Activity

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 8,534 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $427,638.74. Following the sale, the chief executive officer now directly owns 53,635 shares of the company's stock, valued at approximately $2,687,649.85. This trade represents a 13.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Bryan Wahl sold 3,341 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the sale, the general counsel now directly owns 58,057 shares in the company, valued at approximately $2,687,458.53. The trade was a 5.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock worth $1,581,173 over the last 90 days. 8.25% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on TARS shares. HC Wainwright reissued a "buy" rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. The Goldman Sachs Group increased their price objective on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday, May 5th. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Guggenheim increased their price objective on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Finally, Barclays decreased their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $66.33.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.